AI Article Synopsis
- Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a serious condition causing inflammation in blood vessels, mainly affecting the respiratory system.
- A study on seven patients at Cleveland Clinic Abu Dhabi examined the effects of mepolizumab, looking at factors such as vasculitis activity and asthma symptoms before and after treatment.
- Results showed significant improvements, including reduced disease activity and lower doses of prednisolone, indicating that mepolizumab is a safe and effective option for treating EGPA.
Article Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome, is a systemic vasculitis characterized by eosinophil-rich, necrotizing granulomatous inflammation primarily affecting the respiratory tract with necrotizing vasculitis of small- to medium-sized arteries. In this case series, we retrospectively evaluated the efficacy and safety of mepolizumab in seven patients diagnosed with EGPA who presented to the Department of Allergy and Clinical Immunology at Cleveland Clinic Abu Dhabi. The variables assessed before and after mepolizumab treatment included Birmingham Vasculitis Activity Score (BVAS), prednisolone dose, Asthma Control Test (ACT) score, and blood eosinophil count (BEC). We found a significant reduction in BVAS and prednisolone dosage with clinical improvements in asthma symptoms after treatment with mepolizumab. Our case series, the first from the Middle East on the use of mepolizumab in EGPA, demonstrates that mepolizumab is a safe and effective treatment for patients with EGPA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440447 | PMC |
| http://dx.doi.org/10.7759/cureus.68282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.
Cancer Treat Rev
December 2024
SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low metastatic breast cancer (MBC). However, no direct comparison between the two exists, nor with the more recent datopotamab-deruxtecan (Dato-DXd).
Methods: We conducted a network meta-analysis (NMA) to compare efficacy and safety of T-DXd and SG in CT-pretreated HR+ and TN/HER2-low MBC and assess their benefit over standard CT, exploring also a comparison with Dato-DXd.
Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma.
Lung Cancer
December 2024
State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:
Background: Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of non-small-cell lung cancer. This study aims to compare the efficacy and safety of perioperative PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in stage II-IIIB PLELC patients.
Patients And Methods: This retrospective study included stage II-IIIB PLELC patients.
Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease.
J Intern Med
December 2024
Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.
Article Synopsis
- High-intensity statin therapy is effective in reducing mortality and cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), but elderly patients often tolerate moderate-intensity statins better due to intolerance risks.
- A study compared the incidence of statin-associated muscle symptoms (SAMS) and low-density lipoprotein cholesterol (LDL-C) levels in elderly ASCVD patients on either high-intensity statins or moderate-intensity statins combined with ezetimibe.
- Results showed that combination therapy significantly reduced SAMS (0.7% vs 5.7%) while achieving comparable LDL-C target levels (75.4% vs 68.7%), indicating that moderate-intensity therapy with ezetim
The employee's perception of psychological safety: construct dimensions, scale development and validation.
BMC Psychol
December 2024
Teaching and Research Support Center, Air Force Medical University, No.169, Changle West Road, Xi'an, Shaanxi Province, 710032, China.
Although organisations can effectively resist risks and enhance organisational performance by creating a Perception of Psychological Safety (PPS) climate, there is a lack of PPS scales developed under a multidimensional integrated interaction perspective. Based on a review of relevant theories, this paper clearly defines the concept of PPS and proposes a three-dimensional model of PPS, including organisational- level PPS, team- level PPS, and dyadic- level PPS. In this paper, we develop and validate a scale for measuring PPS in the workplace using 12 startups in a relatively economically developed region in the southeastern coastal region of China as the empirical target.
View Article and Find Full Text PDFClinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders.
Orphanet J Rare Dis
December 2024
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, No. 58 Zhongshan Road 2, Guangzhou, 510080, China.
Background: Neuromyelitis Optica Spectrum Disorders (NMOSD) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (AQP4) IgG autoantibodies. Efgartigimod is a human IgG Fc fragment that reduces antibody titers by targeting the neonatal Fc receptor (FcRn). This study documents the efficacy of efgartigimod combined with intravenous methylprednisolone (IVMP) in the acute phase of NMOSD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!